Lanean...
Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals
INTRODUCTION: The FDA issued a warning following 24 cases of HBV reactivation during DAA therapy for HCV, including individuals with inactive, occult and past HBV infection. Clinical presentations ranged from asymptomatic fluctuations in HBV DNA to fulminant hepatic failure, liver transplantation an...
Gorde:
| Argitaratua izan da: | Expert Opin Drug Saf |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5589072/ https://ncbi.nlm.nih.gov/pubmed/28471314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14740338.2017.1325869 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|